News & Updates
Stay informed about HemostOD's latest developments, partnerships, and milestones in our journey to revolutionize platelet therapy.
HemostOD secures a CHF 4.3M seed extension round
The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors.
HemostOD appoints an International Scientific Advisory Board
HemostOD is proud to present the profiles of our distinguished scientific advisors.
HemostOD receives a FIT Tech Growth loan
HemostOD received the support of the "Fondation pour l'Innovation Technologique" (FIT) in the form of a CHF 500'000 loan: the FIT Tech Growth.
HemostOD partners with the biggest transfusion service in Switzerland
The Swiss preclinical biotech company HemostOD and Interregional Blood Transfusion SRC are pleased to announce their partnership to collaborate on the in vitro production of platelets.
HemostOD enters EIT Health's Gold Track Programme
HemostOD has been recognized as a promising healthcare company by a jury of experts. The team will now receive tailored support to grow the company.
Partnering with the Swiss Biotech Center
HemostOD partners with the Swiss Biotech Center to pre-industrialize its technology.
Tech Seed loan
HemostOD receives a loan of CHF 100'000 from the Foundation for Technological Innovation (FIT).
Seed Round
HemostOD raises CHF 1.7M in seed round financing.
Venture Kick II
HemostOD wins Venture Kick's second stage of financial (CHF 40'000) and entrepreneurial support.
Venture Kick I
HemostOD receives the support of Venture Kick's first stage (CHF 10'000).